Dispatch Bio Launches to Develop Novel Solid Tumour Immunotherapies

Dispatch Bio unveiled its Flare platform on 23 July, a first-in-class approach to treating solid tumours using virus-delivered universal antigens that mark cancer cells while disrupting immunosuppressive microenvironments. The technology combines tumour-targeted viral vectors with next-generation CAR-T therapies to trigger a cascade effect, where destroyed tumour cells release additional viral particles to label neighbouring malignancies.

Co-founded in 2022 by CAR-T pioneer Carl June, the company has raised USD 216 million from investors including ARCH Venture Partners and Bristol Myers Squibb to advance its lead candidate into Phase I trials by 2026.

According to PharmCube's MedAlpha® database, six investors participated in Dispatch's Series A. Click here to request a free trial for MedAlpha®.

Subscribe to our newsletter
A weekly newsletter curated for industry professionals. Join thousands of fellow subscribers for free
Subscribe for Free
Daily News
Pfizer Reports USD 28.4b H1'25 Revenue, USD 1.5b from ADCs
2025-08-07
TYK Raises HKD 157m Through Share Placement
2025-08-07
XtalPi and DoveTree Form USD 5.9b AI Drug Discovery Partnership
2025-08-07
Zenitar Bio Secures Nearly RMB 400m in Series B+ Funding
2025-08-07
CSPC Pharma Aims to Challenge Novo's Ozempic in China
2025-08-06
Latest Report
From Reliance to Defiance: A Decade-Long Panorama of China's Innovative Drug Transactions
Details